Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173470
Title: | Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry |
Author: | Cotes Sanchís, Almudena Gallego, Javier Hernandez, Raquel Arrazubi, Virginia Custodio, Ana Cano, Juana María Aguado, Gemma Macias, Ismael Lopez, Carlos López, Flora Visa, Laura Garrido, Marcelo Martínez Lago, Nieves Fernández Montes, Ana Limón, María Luisa Azkarate, Aitor Pimentel, Paola Reguera, Pablo Ramchandani, Avinash Cacho, Juan Diego Martín Carnicero, Alfonso Granja, Mónica Martín Richard, Marta Hernández Pérez, Carolina Hurtado, Alicia Serra, Òlbia Buxo, Elvira Vidal Tocino, Rosario Jimenez Fonseca, Paula Carmona Bayonas, Alberto |
Keywords: | Càncer d'estómac Qualitat de vida Metàstasi Stomach cancer Quality of life Metastasis |
Issue Date: | 31-Jul-2020 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Background: Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. Materials and methods: The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). Results: 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's tau = 0.613), lower in those subjects who received second-line (Kendall's tau = 0.539), especially with ramucirumab+CT (Kendall's tau = 0.413). Conclusion: This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines. |
Note: | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0235848 |
It is part of: | PLoS One, 2020, vol. 15, num. 7, p. e0235848 |
URI: | http://hdl.handle.net/2445/173470 |
Related resource: | https://doi.org/10.1371/journal.pone.0235848 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
SanchisAC.pdf | 1.62 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License